Antibodies to c-Met for the treatment of cancers
OwnerPhillip A. Morton, John A. Arbuckle +4inventors
InventorsPhillip A. Morton, John A. Arbuckle, Michelle L. Evans, William D. Joy, Larry E. Kahn, Jeng-Jong Shieh
Life of this patent
Estimating the term…
Abstract
Antibodies specific for c-Met, a protein tyrosine kinase whose ligand is hepatocyte growth factor (HGF), are provided. The antibodies and fragments thereof may block binding of HGF to c-Met. Antagonist antibodies can be employed to block binding of HGF to c-Met or substantially inhibit c-Met activation. The c-Met antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer, pathological liver conditions, and ophthalmic diseases using the c-Met antibodies are also provided.
Claims40
An antibody or antigen binding portion thereof that specifically binds to c-MET, wherein said antibody comprises a c-MET antibody selected from the group consisting of PGIA-01-A1, PGIA-01-A2, PGIA-01-A3, PGIA-01-A4, PGIA-01-A5, PGIA-01-A6, PGIA-01-A7, PGIA-01-A8, PGIA-01-A9, PGIA-01-A10, PGIA-01-A11, PGIA-01-A12, PGIA-01-B1, PGIA-01-B2, PGIA-02-A1, PGIA-02-A2, PGIA-02-A3, PGIA-02-A4, PGIA-02-A5, PGIA-02-A6, PGIA-02-A7, PGIA-02-A8, PGIA-02-A9, PGIA-02-A10, PGIA-02-A11, PGIA-02-A12, PGIA-02-B1, PGIA-03-A1, PGIA-03-A2, PGIA-03-A3, PGIA-03-A4, PGIA-03-A5, PGIA-03-A6, PGIA-03-A7, PGIA-03-A8, PGIA-03-A9, PGIA-03-A10, PGIA-03-A11, PGIA-03-A12, PGIA-03-B1, PGIA-03-B2, PGIA-03-B3, PGIA-03-B4, PGIA-03-B5, PGIA-03-B6, PGIA-03-B7, PGIA-03-B8, PGIA-04-A1, PGIA-04-A2, PGIA-04-A3, PGIA-04-A4, PGIA-04-A5, PGIA-04-A6, PGIA-04-A7, PGIA-04-A8, PGIA-04-A9, PGIA-04-A10, PGIA-04-A11, PGIA-04-A12, and PGIA-05-A1 or fragment of any one thereof.
Dependencies are inferred from the claim text.